Capsule Summary Slidesets

Share

Program Content

Activities

  • Gilteritinib in ND AML
    Phase I Study of Gilteritinib Combined With Induction/Consolidation Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia: Final Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2020

    Expires: December 06, 2021

  • Magrolimab + Aza in AML
    Phase Ib Efficacy, Safety of Anti-CD47 Antibody Magrolimab + Azacitidine in Untreated AML
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2020

    Expires: December 06, 2021

  • QUAZAR AML-001
    Phase III QUAZAR AML-001: Analyses of CC-486 (Oral Azacitidine) vs Placebo as Maintenance Therapy in AML After CR/CRi
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2020

    Expires: December 08, 2021

  • OPTIC Interim Analysis
    Randomized Phase II OPTIC Trial of 3 Starting Doses of Ponatinib in Patients With CP-CML: Analysis by Mutation Status and Line of Therapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2020

    Expires: December 09, 2021

  • Hyper-CVAD + Blinatumomab in B-Cell ALL
    Phase II Study of Hyper-CVAD + Blinatumomab in Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2020

    Expires: December 10, 2021

  • QUAZAR AML-001: MRD
    QUAZAR AML-001 Phase III Trial of Oral AZA (CC-486) vs Placebo as Maintenance Therapy in AML After First Remission: Analyses by MRD Status
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2020

    Expires: December 13, 2021

  • ASCEMBL
    ASCEMBL: Phase III Study of STAMP Inhibitor Asciminib vs Bosutinib for CML-CP Previously Treated With ≥ 2 TKIs
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2020

    Expires: December 13, 2021

  • Flotetuzumab in AML
    Phase I/II Trial of Flotetuzumab as Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2020

    Expires: December 14, 2021

  • Ponatinib After Sec-Gen TKI
    Ponatinib After Progression on Second-Generation TKI Therapy in Chronic-Phase Chronic Myeloid Leukemia: Combined Analysis of PACE and OPTIC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2020

    Expires: December 14, 2021

  • Asciminib in <i>T315I</i> CML
    Updated Analysis of Phase I Trial of Asciminib, a First-in-Class STAMP Inhibitor, in Patients With Previously Treated BCR-ABL1 T315I–Mutated CML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2020

    Expires: December 15, 2021

Provided by

ProCE Banner

Supporters

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology